Opus Genetics reports Cohort 1 data for OPGx-BEST1, aligns with FDA on pivotal endpointSep 9Clinical readoutOcuphire Pharma, Inc.
Viatris: Ocuphire trial results posted, Amnesteem label update, gabapentin abuse study completedAug 21Weekly roundup, 3 itemsalprazolamgabapentin
Ocuphire's Phase 3 VEGA-3 presbyopia trial posts results on ClinicalTrials.govAug 17Trial updateOcuphire Pharma, Inc.
Opus Genetics reports Q2 2026 results, cites September BEST1 data and LCA5 dosing planAug 6Quarterly updateOcuphire Pharma, Inc.
Sign in